Effectiveness of Second MRNA COVID-19 Booster Vaccine in Immunocompromised Persons and Long-Term Care Facility Residents

Overview

Journal Emerg Infect Dis

Specialty Infectious Diseases

Date 2022 Oct 3

PMID 36191615

Authors

Yoo-Yeon Kim

Young June Choe

Jia Kim

Ryu Kyung Kim

Eun Jung Jang

Seon Kyeong Park

Do-Sang Lim

Seonju Yi

Sangwon Lee

Geun-Yong Kwon

Jee Yeon Shin

Sang-Yoon Choi

Mi Jin Jeong

Young-Joon Park

Affiliations

Soon will be listed here.

Abstract

We used a nationwide population registry in South Korea to estimate the effect of a second booster dose of mRNA COVID-19 vaccine on the risk for laboratory-confirmed SARS-CoV-2 infection, critical infection, and death in immunocompromised persons and long-term care facility (LTCF) residents. During February 16-May 7, 2022, among 972,449 eligible persons, 736,439 (75.7%) received a first booster and 236,010 (24.3%) persons received a second booster. Compared with the first booster group, at 30-53 days, the second booster recipients had vaccine effectiveness (VE) against all infections of 22.28% (95% CI 19.35%-25.11%), VE against critical infection of 56.95% (95% CI 29.99%-73.53%), and VE against death of 62.96% (95% CI 34.18%-79.15%). Our findings provide real-world evidence that a second booster dose of mRNA vaccine substantially increases protection against critical infection and death in these high-risk population groups.

Citing Articles

Uptake, effectiveness and safety of COVID-19 vaccines in individuals at clinical risk due to immunosuppressive drug therapy or transplantation procedures: a population-based cohort study in England.

Chen D, Copland E, Hirst J, Mi E, Dixon S, Coupland C BMC Med. 2024; 22(1):237.

PMID: 38858672 PMC: 11165729. DOI: 10.1186/s12916-024-03457-1.

Design and analysis heterogeneity in observational studies of COVID-19 booster effectiveness: A review and case study.

Meah S, Shi X, Fritsche L, Salvatore M, Wagner A, Martin E Sci Adv. 2023; 9(51):eadj3747.

PMID: 38117882 PMC: 10732535. DOI: 10.1126/sciadv.adj3747.

Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong.

Cheung Y, Lau E, Yin G, Lin Y, Cowling B, Lam K Emerg Infect Dis. 2023; 30(1):70-78.

PMID: 38040664 PMC: 10756371. DOI: 10.3201/eid3001.230414.

Comparative Effectiveness of COVID-19 Bivalent Versus Monovalent mRNA Vaccines in the Early Stage of Bivalent Vaccination in Korea: October 2022 to January 2023.

Kim R, Choe Y, Jang E, Chae C, Hwang J, Lee K J Korean Med Sci. 2023; 38(46):e396.

PMID: 38013649 PMC: 10681846. DOI: 10.3346/jkms.2023.38.e396.

Predicting the Public Health Impact of Bivalent Vaccines and Nirmatrelvir-Ritonavir Against Coronavirus Disease 2019.

Park H, Tan S, Leon T, Jain S, Schechter R, Lo N Open Forum Infect Dis. 2023; 10(9):ofad415.

PMID: 37674629 PMC: 10478155. DOI: 10.1093/ofid/ofad415.

References

Bar-On Y, Goldberg Y, Mandel M, Bodenheimer O, Amir O, Freedman L . Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. N Engl J Med. 2022; 386(18):1712-1720. PMC: 9006780. DOI: 10.1056/NEJMoa2201570. View

Tenforde M, Patel M, Gaglani M, Ginde A, Douin D, Talbot H . Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults - United States, August-December 2021. MMWR Morb Mortal Wkly Rep. 2022; 71(4):118-124. PMC: 9351530. DOI: 10.15585/mmwr.mm7104a2. View

Nordstrom P, Ballin M, Nordstrom A . Effectiveness of a fourth dose of mRNA COVID-19 vaccine against all-cause mortality in long-term care facility residents and in the oldest old: A nationwide, retrospective cohort study in Sweden. Lancet Reg Health Eur. 2022; 21:100466. PMC: 9277096. DOI: 10.1016/j.lanepe.2022.100466. View

Minka S, Minka F . A tabulated summary of the evidence on humoral and cellular responses to the SARS-CoV-2 Omicron VOC, as well as vaccine efficacy against this variant. Immunol Lett. 2022; 243:38-43. PMC: 8815275. DOI: 10.1016/j.imlet.2022.02.002. View

Yi S, Choe Y, Lim D, Lee H, Kim J, Kim Y . Impact of national Covid-19 vaccination Campaign, South Korea. Vaccine. 2022; 40(26):3670-3675. PMC: 9080122. DOI: 10.1016/j.vaccine.2022.05.002. View

Sanchez Ruiz M, Adonias G, Robaglia-Schlupp A, Rapilly F, Chabert M, Ramalli L . Effectiveness of mRNA BNT162b2 COVID-19 vaccine against SARS-CoV-2 Delta variant among elderly residents from a long-term care facility, South of France, May 2021. Eur Rev Med Pharmacol Sci. 2022; 26(7):2586-2591. DOI: 10.26355/eurrev_202204_28496. View

Kim E, Choe Y, Park H, Jeong H, Chung J, Yu J . Community Transmission of SARS-CoV-2 Omicron Variant, South Korea, 2021. Emerg Infect Dis. 2022; 28(4):898-900. PMC: 8962914. DOI: 10.3201/eid2804.220006. View

Sheikh A, Kerr S, Woolhouse M, McMenamin J, Robertson C . Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design. Lancet Infect Dis. 2022; 22(7):959-966. PMC: 9033213. DOI: 10.1016/S1473-3099(22)00141-4. View

Garcia-Beltran W, Denis K, Hoelzemer A, Lam E, Nitido A, Sheehan M . mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell. 2022; 185(3):457-466.e4. PMC: 8733787. DOI: 10.1016/j.cell.2021.12.033. View

10.

Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R . Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. N Engl J Med. 2022; 386(4):340-350. PMC: 8781262. DOI: 10.1056/NEJMoa2115481. View

11.

Abu-Raddad L, Chemaitelly H, Bertollini R . Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar. N Engl J Med. 2022; 386(11):1091-1093. PMC: 8809505. DOI: 10.1056/NEJMc2119432. View

12.

Munro A, Feng S, Janani L, Cornelius V, Aley P, Babbage G . Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2,.... Lancet Infect Dis. 2022; 22(8):1131-1141. PMC: 9084623. DOI: 10.1016/S1473-3099(22)00271-7. View

13.

Lee A, Wong S, Chai L, Lee S, Lee M, Muthiah M . Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022; 376:e068632. PMC: 8889026. DOI: 10.1136/bmj-2021-068632. View

14.

Monge S, Rojas-Benedicto A, Olmedo C, Mazagatos C, Sierra M, Limia A . Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study. Lancet Infect Dis. 2022; 22(9):1313-1320. PMC: 9162477. DOI: 10.1016/S1473-3099(22)00292-4. View

15.

Magen O, Waxman J, Makov-Assif M, Vered R, Dicker D, Hernan M . Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med. 2022; 386(17):1603-1614. PMC: 9020581. DOI: 10.1056/NEJMoa2201688. View

16.

Paranthaman K, Subbarao S, Andrews N, Kirsebom F, Gower C, Lopez-Bernal J . Effectiveness of BNT162b2 and ChAdOx-1 vaccines in residents of long-term care facilities in England using a time-varying proportional hazards model. Age Ageing. 2022; 51(5). PMC: 9382883. DOI: 10.1093/ageing/afac115. View